Merck Gains Positive Regulatory Nods For Dulera And Brinavess
Executive Summary
Merck received two pieces of good news from regulatory authorities within a few days - first an FDA approval for its asthma drug Dulera, then a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for its intravenous atrial fibrillation drug Brinavess
You may also be interested in...
Merck And Cardiome Obtain EU Approval For Vernakalant In Atrial Fibrillation
First of several anticipated approvals for the AF drug nets Cardiome a $30 million milestone payment from Merck.
Merck And Cardiome Obtain EU Approval For Vernakalant In Atrial Fibrillation
First of several anticipated approvals for the AF drug nets Cardiome a $30 million milestone payment from Merck.
LABA Safety Studies, REMS Are Next Topics For Sponsors, FDA After Relabeling
Discussions about how best to study the safety of long-acting beta agonists are ready to resume now that FDA has issued a revised label for the drug class